TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder

Brain, Behavior, and Immunity

Volumn 59, Issue , 2017, Pages 265-272

  Hung, Yi Yung ^a   Lin, Chin Chuen ^a   Kang, Hong Yo ^a,b   Huang, Tiao Lai ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antidepressants; Inflammation; Innate immunity; Major depressive disorder; Negative regulation; Toll like receptor

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 6; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 RECEPTOR RELATED RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF TUMORIGENICITY 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT; IL6 PROTEIN, HUMAN; SMALL INTERFERING RNA; TNFAIP3 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; HAMILTON DEPRESSION RATING SCALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICROGLIA; MONOCYTE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SMOKING; ANIMAL; BIOSYNTHESIS; CELL LINE; GENETICS; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOMARKERS; CELL LINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; INTERLEUKIN-6; MALE; MICE; MICROGLIA; MIDDLE AGED; MONOCYTES; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3;

EID: 85002050785     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.09.014     Document Type: Article

References (46)

1. Alcocer-Gomez, E., Ulecia-Moron, C., Marin-Aguilar, F., Rybkina, T., Casas-Barquero, N., Ruiz-Cabello, J., et al. Stress-induced depressive behaviors require a functional NLRP3 inflammasome. Mol. Neurobiol. 53:7 (2016), 4874–4882.
2. Baharav, E., Bar, M., Taler, M., Gil-Ad, I., Karp, L., Weinberger, A., et al. Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. NeuroImmunoModulation 19:5 (2012), 309–318.
3. Barzman, D., Eliassen, J., McNamara, R., Abonia, P., Mossman, D., Durling, M., et al. Correlations of inflammatory gene pathways, corticolimbic functional activities, and aggression in pediatric bipolar disorder: a preliminary study. Psychiatry Res. 224:2 (2014), 107–111.
4. Branco-de-Almeida, L.S., Franco, G.C., Castro, M.L., Dos Santos, J.G., Anbinder, A.L., Cortelli, S.C., et al. Fluoxetine inhibits inflammatory response and bone loss in a rat model of ligature-induced periodontitis. J. Periodontol. 83:5 (2012), 664–671.
5. Breese, G.R., Knapp, D.J., Overstreet, D.H., Navarro, M., Wills, T.A., Angel, R.A., Repeated lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced anxiety-like behavior. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 33:4 (2008), 867–876.
6. Cheng, Y., Pardo, M., Armini, R.S., Martinez, A., Mouhsine, H., Zagury, J.F., et al. Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav. Immun. 53 (2016), 207–222.
7. Crupi, R., Cuzzocrea, S., Neuroinflammation and immunity: a new pharmacological target in depression. CNS Neurol. Disord.: Drug Targets 15:4 (2016), 464–476.
8. Dalal, N.V., Pranski, E.L., Tansey, M.G., Lah, J.J., Levey, A.I., Betarbet, R.S., RNF11 modulates microglia activation through NF-kappaB signalling cascade. Neurosci. Lett. 528:2 (2012), 174–179.
9. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:5 (2010), 446–457.
10. Duong, B.H., Onizawa, M., Oses-Prieto, J.A., Advincula, R., Burlingame, A., Malynn, B.A., et al. A20 restricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42:1 (2015), 55–67.
11. Durairaj, H., Steury, M.D., Parameswaran, N., Paroxetine differentially modulates LPS-induced TNFalpha and IL-6 production in mouse macrophages. Int. Immunopharmacol. 25:2 (2015), 485–492.
12. Garate, I., Garcia-Bueno, B., Madrigal, J.L., Caso, J.R., Alou, L., Gomez-Lus, M.L., et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J. Neuroinflamm., 11, 2014, 8.
13. Guedes, R.P., Csizmadia, E., Moll, H.P., Ma, A., Ferran, C., da Silva, C.G., A20 deficiency causes spontaneous neuroinflammation in mice. J. Neuroinflamm., 11, 2014, 122.
14. Han, J.W., Wang, Y., Li, H.B., Alateng, C., Bai, Y.H., Sun, Z.Q., et al. Single nucleotide polymorphisms of TNFAIP3 are associated with systemic lupus erythematosus in Han Chinese population. Int. J. Immunogenet. 43:2 (2016), 96–100.
15. Haroon, E., Raison, C.L., Miller, A.H., Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 37:1 (2012), 137–162.
16. Henry, R.J., Kerr, D.M., Finn, D.P., Roche, M., For whom the endocannabinoid tolls: modulation of innate immune function and implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 64 (2016), 167–180.
17. Hung, Y.Y., Huang, K.W., Kang, H.Y., Huang, G.Y., Huang, T.L., Antidepressants normalize elevated Toll-like receptor profile in major depressive disorder. Psychopharmacology 233:9 (2016), 1707–1714.
18. Hung, Y.Y., Kang, H.Y., Huang, K.W., Huang, T.L., Association between toll-like receptors expression and major depressive disorder. Psychiatry Res. 220:1–2 (2014), 283–286.
19. Koh, S.J., Kim, J.M., Kim, I.K., Kim, N., Jung, H.C., Song, I.S., et al. Fluoxetine inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 301:1 (2011), G9–19.
20. Li, M., Shi, X., Qian, T., Li, J., Tian, Z., Ni, B., et al. A20 overexpression alleviates pristine-induced lupus nephritis by inhibiting the NF-κB and NLRP3 inflammasome activation in macrophages of mice. Int. J. Clin. Exp. Med. 8:10 (2015), 17430–17440.
21. Liew, F.Y., Xu, D., Brint, E.K., O'Neill, L.A., Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5:6 (2005), 446–458.
22. Maes, M., Nowak, G., Caso, J.R., Leza, J.C., Song, C., Kubera, M., et al. Toward omics-based, systems biomedicine, and path and drug discovery methodologies for depression-inflammation research. Mol. Neurobiol., 2015.
23. Maes, M., Song, C., Lin, A.H., Bonaccorso, S., Kenis, G., De Jongh, R., et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 20:4 (1999), 370–379.
24. Marian, G., Nica, E.A., Ionescu, B.E., Carlogea, D.G., Depression as an initial feature of systemic lupus erythematosus? A case report. J. Med. Life 3:2 (2010), 183–185.
25. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16:1 (2016), 22–34.
26. Myint, A.M., Kim, Y.K., Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 304–313.
27. Nishino, S., Ueno, R., Ohishi, K., Sakai, T., Hayaishi, O., Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry 146:3 (1989), 365–368.
28. Ohgi, Y., Futamura, T., Kikuchi, T., Hashimoto, K., Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 103:4 (2013), 853–859.
29. Padmos, R.C., Hillegers, M.H., Knijff, E.M., Vonk, R., Bouvy, A., Staal, F.J., et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65:4 (2008), 395–407.
30. Plant, D., Farragher, T., Flynn, E., Martin, P., Eyre, S., Bunn, D., et al. A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Pharmacogenomics J. 12:2 (2012), 128–133.
31. Pranski, E.L., Van Sanford, C.D., Dalal, N.V., Orr, A.L., Karmali, D., Cooper, D.S., et al. Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain. Neurosci. Lett. 520:1 (2012), 104–109.
32. Ruiz-Larranaga, O., Uribarri, M., Alcaro, M.C., Escorza-Trevino, S., Del Amo, J., Iriondo, M., et al. Genetic variants associated with rheumatoid arthritis patients and serotypes in European populations. Clin. Exp. Rheumatol., 2016.
33. Sacre, S., Medghalchi, M., Gregory, B., Brennan, F., Williams, R., Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 62:3 (2010), 683–693.
34. Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., Kirchner, H., Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr. Scand. 94:3 (1996), 198–204.
35. Shembade, N., Harhaj, E.W., Regulation of NF-kappaB signaling by the A20 deubiquitinase. Cell. Mol. Immunol. 9:2 (2012), 123–130.
36. Tsai, J.H., Kuo, C.H., Yang, P., Cheng, K.H., Wang, P.W., Chen, C.C., et al. Effects of antidepressants on IP-10 production in LPS-activated THP-1 human monocytes. Int. J. Mol. Sci. 15:8 (2014), 13223–13235.
37. Tynan, R.J., Weidenhofer, J., Hinwood, M., Cairns, M.J., Day, T.A., Walker, F.R., A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun. 26:3 (2012), 469–479.
38. van Exel, E., Jacobs, J., Korswagen, L.A., Voskuyl, A.E., Stek, M., Dekker, J., et al. Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus 22:14 (2013), 1462–1469.
39. Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossoul, A., Verheugen, E., Vogel, P., et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512:7512 (2014), 69–73.
40. Vogelzangs, N., Beekman, A.T., van Reedt Dortland, A.K., Schoevers, R.A., Giltay, E.J., de Jonge, P., et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 39:7 (2014), 1624–1634.
41. Waiskopf, N., Ofek, K., Gilboa-Geffen, A., Bekenstein, U., Bahat, A., Bennett, E.R., et al. AChE and RACK1 promote the anti-inflammatory properties of fluoxetine. J. Mol. Neurosci.: MN 53:3 (2014), 306–315.
42. Walker, F.R., A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology 67 (2013), 304–317.
43. Wang, X., Deckert, M., Xuan, N.T., Nishanth, G., Just, S., Waisman, A., et al. Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-kappaB- and STAT1-dependent chemokine production in astrocytes. Acta Neuropathol., 2013.
44. Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:9904 (2013), 1575–1586.
45. Wu, M.K., Huang, T.L., Huang, K.W., Huang, Y.L., Hung, Y.Y., Association between toll-like receptor 4 expression and symptoms of major depressive disorder. Neuropsychiatr. Dis. Treat. 11 (2015), 1853–1857.
46. Yu, L., Miao, H., Hou, Y., Zhang, B., Guo, L., Neuroprotective effect of A20 on TNF-induced postischemic apoptosis. Neurochem. Res. 31:1 (2006), 21–32.